The blood screening is a medical process that is conducted to examine the blood over a specific condition and it further helps in monitoring disease with a variety of other conditions associated to infection or the disease. The blood screening technology is widely used over various fields of diagnostics of diseases such as HIV, Cancer, and infections. Additionally, blood screening also helps in the growth of prominent diseases incorporation of nucleic acid amplification test and the other advancements in blood screening tests. As a result, demand & adoption for blood screening would increase thereby, making its way for the growth of the market.
According to study, “Global Blood Screening Market to reach USD 3.94 billion by 2026” the key companies operating in the global blood screening market is Grifols S.A, Abbott Laboratories, F. Hoffmann-La Rochen AG, Becton, Dickson and Company, Biomerieux, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics, Danaher Corporation, and Siemens Healthineers AG.
Based on the product, the blood screening market is segmented as instruments, reagents & kits, and software & services. The reagents & kits segment is further sub-segmented as ELISA kit, NAT kit, and others. NAT reagents include enzymes & polymerases, probes & primers, standards & controls, nucleotides & solutions, buffers, and labeling & detection reagents. Additionally, ELISA reagents & kits include immunosorbents, conjugates (an antigen or antibody-conjugated enzyme), controls, and others. Based on disease type, the market is segmented as respiratory diseases, cholesterol, HIV/aids, cold & flu, diabetes mellitus, oncology, infectious diseases, others. Based on technology, the market is segmented as ELISA technology, Nucleic Acid Testing (NAT) technology (Real-time PCR and Transcription Mediated Amplification (TMA)), platform (Fluorescence Immunoassays (FIA), Chemiluminescence Immunoassay (CLIA) and Colorimetric Immunoassay (CI)), Next Generation Sequencing (NGS), Western Blot Assays, rapid tests, and others. Also, based on end-user, the market is segmented as hospitals, blood banks, and others.
The blood screening market is driven by an increase in the prevalence of infectious diseases, followed by a rise in awareness about healthcare, growth in technological advancements in blood screening technologies, increase in number of blood donations, rise in healthcare initiatives by government, increase in healthcare expenditure, and a surge in adoption of nucleic acid amplification test (NAT). However, the dearth of skilled manpower, stringent regulatory approvals and high operating costs may impact the market. Moreover, introduction of pathogen reduction technology or microbiology screening & multiplexing are key opportunities for the market.
Based on geography, the North-American region holds a major share in the global blood screening market owing to the rise in the prevalence of infectious diseases along with an increase in demand for donated blood in the region. Whereas, the Asian-Pacific and European regions are anticipated to witness higher growth rate due to rise in public-private the initiative aimed towards increasing advance research practices and growth in investment to promote blood screening research over the forecast period. In upcoming years, it is projected that the future of the global market will be bright as a result of the presence of the well-established infrastructure for hospitals & clinical laboratories coupled with the rise in prevalence of newer pathogens during the forecast period. The global blood screening market is valued approximately at US $2.02 billion in 2018 and is expected to grow with a healthy growth rate of more than 8.70% over the forecast period 2019 to 2026.
For More Information on the Research Report, refer to below links: –
Related Report: –
Contact Us: –
Ankur Gupta, Head Marketing & Communications